We propose enhancing this strategy in CLL patients through combination drug approaches by simultaneously giving CSF1R inhibitors, which target NLCs, with BTK and/or PI3Kδ inhibitors as well as other agents, which target the leukemia cells themselves. This evidence concerns the gene CSF1R and leukemia.